| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2013-06-510453 |
| P698 | PubMed publication ID | 24072855 |
| P50 | author | Jesús San Miguel | Q5930658 |
| Ramón García-Sanz | Q37830539 | ||
| Norma C. Gutiérrez | Q39399978 | ||
| María-Belén Vidriales | Q51533824 | ||
| Mercedes Garayoa | Q51693206 | ||
| Enrique M Ocio | Q60324819 | ||
| Luis A Corchete | Q83437761 | ||
| Bruno Paiva | Q88009013 | ||
| Alberto Orfao | Q89543246 | ||
| María Victoria Mateos | Q89582275 | ||
| Laura San-Segundo | Q100312937 | ||
| Irene Aires-Mejia | Q117261656 | ||
| P2093 | author name string | Montserrat Martín | |
| Paloma Bárcena | |||
| Cristina Jimenez | |||
| María-Luz Sanchez | |||
| Ines Mota | |||
| Jose-Maria Sayagues | |||
| Teresa Paino | |||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | 3591-3598 | |
| P577 | publication date | 2013-09-26 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile | |
| P478 | volume | 122 |
| Q37032148 | A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma |
| Q52579654 | Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. |
| Q41556524 | Assessment of minimal residual disease in myeloma and the need for a consensus approach |
| Q99552452 | Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response |
| Q47125786 | CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma |
| Q88666891 | Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease |
| Q38249930 | Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques |
| Q47110039 | Current applications of multiparameter flow cytometry in plasma cell disorders |
| Q59811510 | Daily rhythms influence the ability of lung-derived extracellular vesicles to modulate bone marrow cell phenotype |
| Q26771228 | Deep Response in Multiple Myeloma: A Critical Review |
| Q55208548 | Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma. |
| Q51751162 | Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma. |
| Q33712516 | Differentiation stage of myeloma plasma cells: biological and clinical significance. |
| Q47409821 | Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation |
| Q55443199 | Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study. |
| Q38895512 | Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. |
| Q37662286 | Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. |
| Q57790423 | Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis |
| Q33664484 | Genetic interrogation of circulating multiple myeloma cells at single-cell resolution |
| Q47314920 | Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma |
| Q30843897 | Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device |
| Q48160190 | Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics |
| Q93088915 | Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives |
| Q50092746 | Minimal residual disease analysis in myeloma - when, why and where. |
| Q61798674 | Molecular Players in Hematologic Tumor Cell Trafficking |
| Q59135626 | Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC) |
| Q60203335 | Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential |
| Q41928814 | Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer |
| Q89066166 | Potential Clinical Application of Genomics in Multiple Myeloma |
| Q88608191 | Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma |
| Q53831599 | Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. |
| Q41007930 | Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis. |
| Q33621587 | Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma |
| Q34173892 | Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. |
| Q34416126 | Quantification of clonal circulating plasma cells in relapsed multiple myeloma |
| Q41091821 | Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. |
| Q34448984 | Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells. |
| Q41230421 | Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation |
| Q41436943 | Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing |
| Q38970585 | Targeting the Bone Marrow Microenvironment. |
| Q36242936 | Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion |
| Q37641783 | Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. |
| Q36673465 | The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective |
| Q90080673 | Tracking myeloma tumor DNA in peripheral blood |
| Q90598650 | Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination |
| Q90389807 | Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma |
| Q85502173 | Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases |
| Q38256196 | What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series |
Search more.